Abstrakt

Toll-like receptors (TLR), especially TLR3, 7 and 9, play an important role in the pathogenesis of systemic lupus erythematosus (SLE). In our study blood was collected from 16 patients with SLE and from 8 healthy volunteers. Concentrations of IL-6, IL-10 and sIL-2R were measured by ELISA in mononuclear cell culture supernatant after 24 hours of stimulation by agonists and antagonists of TLR3 and 9 (for TLR3-poli I/C, resveratrol and for TLR9-ODN2006, IRS 945). Stimulation of TLR9 by ODN2006 led to an increase of IL-6 concentration in cell culture supernatants from the cells of healthy volunteers compared with unstimulated cells from controls. Inhibition of TLR3 activation by resveratrol caused a significantly lower concentration of IL-10 in cell culture supernatants derived from both patients and healthy donors. Moreover, resveratrol significantly decreased the level of IL-10 and sIL-2R in culture supernatants of cells derived from patients with active disease compared to the inactive stage. A positive correlation was also found between IL-6 concentration following ODN2006 administration and disease activity. In conclusions, our results indicate that TLRs play a role in the modulation of the inflammatory response in SLE patients. This suppressive action on IL-10 synthesis demonstrated by resveratrol suggests that it may be useful in SLE therapy.

Przypisy

• 1. Barrat F.J., Meeker T., Chan J.H., Guiducci C., Coffman R.L.: Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol., 2007; 37: 3582-3586
  Google Scholar
• 2. Barrat F.J., Meeker T., Gregorio J., Chan J.H., Uematsu S., Akira S., Chang B., Duramad O., Coffman R.L.: Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med., 2005; 202: 1131-1139
  Google Scholar
• 3. Bijl M., Limburg P.C., Kahlenberg C.G.: New insights into the pathogenesis of systemic lupus erythematosus (SLE): the role of apoptosis. Neth. J. Med., 2001; 59: 66-75
  Google Scholar
• 4. Dejica D.: Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy. Roum. Arch. Microbiol. Immunol., 2001; 60: 183-201
  Google Scholar
• 5. Esposito P., Balletta M.M., Procino A., Postiglione L., Memoli B.: Interleukin-6 release from peripheral mononuclear cells is associated to disease activity and treatment response in patients with lupus nephritis. Lupus, 2009; 18: 1329-1330
  Google Scholar
• 6. Hurst J., von Landenberg P.: Toll-like receptors and autoimmunity. Autoimmun. Rev., 2008; 7: 204-208
  Google Scholar
• 7. Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., Howard M.: Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med., 1994; 179: 305-310
  Google Scholar
• 8. Kicielińska J., Pajtasz-Piasecka E.: Rola IL-10 w modulowaniu odpowiedzi odpornościowej w warunkach prawidłowych oraz w środowisku nowotworu. Postępy Hig. Med. Dośw., 2014; 68: 879-892
  Google Scholar
• 9. Laut J., Senitzer D., Petrucci R., Sablay L.B., Barland P., Glicklich D.: Soluble interleukin-2 receptor levels in lupus nephritis. Clin. Nephrol., 1992; 38: 179-184
  Google Scholar
• 10. Liu P., Song J., Su H., Li L., Lu N., Yang R., Peng Z.: IL-10 gene polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis. PLoS One, 2013; 8: e69547
  Google Scholar
• 11. Lourenço E.V., La Cava A.: Cytokines in systemic lupus erythematosus. Curr. Mol. Med., 2009; 9: 242-254
  Google Scholar
• 12. Maidhof W., Hilas O.: Lupus: an overview of the disease and management options. Pharmacy Therapeutics, 2012; 37: 240-246
  Google Scholar
• 13. Nakano S., Morimoto S., Suzuki J., Nozawa K., Amano H., Tokano Y., Takasaki Y.: Role of pathogenic auto-antibody production by Tolllike receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology, 2008; 47: 145-149
  Google Scholar
• 14. Papadimitraki E.D., Bertsias G.K., Boumpas D.T.: Toll like receptors and autoimmunity: a critical appraisal. J. Autoimmun., 2007; 29: 310-318
  Google Scholar
• 15. Park Y.B., Lee S.K., Kim D.S., Lee J., Lee C.H., Song C.H.: Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol., 1998; 16: 283-288
  Google Scholar
• 16. Patole P.S., Gröne H.J., Segerer S., Ciubar R., Belemezova E., Henger A., Kretzler M., Schlöndorff D., Anders H.J.: Viral double stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J. Am. Soc. Nephrol., 2005; 16: 1326-1338
  Google Scholar
• 17. Pawar R.D., Patole P.S., Ellwart A., Lech M., Segerer S., Schlondorff D., Anders H.J.: Ligands to nucleic acid-specific Toll-like receptors and the onset of lupus nephritis. J. Am. Soc. Nephrol., 2006; 17: 3365-3373
  Google Scholar
• 18. Pawar R.D., Ramanjaneyulu A., Kulkarni O.P., Lech M., Segerer S., Anders H.J.: Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J. Am. Soc. Nephrol., 2007; 18: 1721-1731
  Google Scholar
• 19. Robak E., Sysa-Jędrzejowska A., Robak T., Stępień H., Woźniacka A., Waszczykowska E.: Tumour necrosis factor α (TNF-α), interleukin-6 (IL-6) and their soluble receptors (sTNF-α-Rp55 and slL-6R) serum levels in systemic lupus erythematodes. Mediators Inflamm., 1996; 5: 435-441
  Google Scholar
• 20. Sabry A., Sheashaa H., El-Husseini A., Mahmoud K., Eldahshan K.F., George S.K., Abdel-Khalek E., El-Shafey E.M., Abo-Zenah H.: Proinflammatory cytokines (TNF-αand IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine, 2006; 35: 148-153
  Google Scholar
• 21. Sharma S., Chopra K., Kulkarni S.K., Agrewala J.N.: Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin. Exp. Immunol., 2007; 147: 155-163
  Google Scholar
• 22. Singh N., Singh U., Nagarkatti P., Nagarkatti M.: Resveratrol ameliorates lupus by epigenetic modulation of Foxp3 and IL-17 genes resulting in differential regulation of regulatory T cells and Th17 cells via activation of aryl hydrocarbon receptor (P5129). J. Immunol., 2013; 190 (Suppl.): 137.6
  Google Scholar
• 23. Tokano Y., Murashima A., Takasaki Y., Hashimoto H., Okumura K., Hirose S.: Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann. Rheum. Dis., 1989; 48: 803-809
  Google Scholar
• 24. Tsao J.T., Hsieh S.C., Chiang B.L., Yu C.L., Lin S.C.: Altered IL-10 and TNF-α production in peripheral blood mononuclear cells of systemic lupus erythematosus patients after Toll-like receptor 2, 4, or 9 activation. Clin. Exp. Med., 2012; 12: 153-158
  Google Scholar
• 25. Wallace D.J., Linker-Israeli M., Metzger A.L., Stecher V.J.: The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus, 1993; 2 (Suppl. 1): S13-S15
  Google Scholar
• 25.
  Google Scholar
• 27. Wong C.K., Wong P.T., Tam L.S., Li E.K., Chen D.P., Lam C.W.: Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin. Exp. Immunol., 2010; 159: 11-22
  Google Scholar
• 28. Wong K.L., Wong R.P.: Serum soluble interleukin 2 receptor in systemic lupus erythematosus: effects of disease activity and infection. Ann. Rheum. Dis., 1991; 50: 706-709
  Google Scholar
• 29. Xuzhu G., Komai-Koma M., Leung B.P., Howe H.S., McSharry C., McInnes I.B., Xu D.: Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann. Rheum. Dis., 2012; 71: 129-135
  Google Scholar
• 30. Yeo S.J., Yoon J.G., Hong S.C., Yi A.K.: CpG DNA induces self and cross-hyporesponsiveness of RAW264.7 cells in response to CpG DNAand lipopolysaccharide: alterations in IL-1 receptor-associated kinase expression. J. Immunol., 2003; 170: 1052-1061
  Google Scholar
• 31. Youn H.S., Lee J.Y., Fitzgerald K.A., Young H.A., Akira S., Hwang D.H.: Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J. Immunol., 2005; 175: 3339-3346
  Google Scholar
• 32. Yuan W., DiMartino S.J., Redecha P.B., Ivashkiv L.B., Salmon J.E.: Systemic lupus erythematosus monocytes are less responsive to interleukin-10 in the presence of immune complexes. ArthritisRheum., 2011; 63: 212-218
  Google Scholar
• 33. Zhu F.G., Jiang W., Bhagat L., Wang D., Yu D., Tang J.X., Kandimalla E.R., La Monica N., Agrawal S.: A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice. Autoimmunity, 2013; 46: 419-428
  Google Scholar

Pełna treść artykułu